Compounds > 4,4'-dithiodimorpholine
Page last updated: 2024-11-05

4,4'-dithiodimorpholine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

4,4'-Dithiodimorpholine is a sulfur-containing compound with two morpholine rings linked by a disulfide bond. It is a white crystalline solid that is soluble in organic solvents. The compound has been studied for its potential use as a vulcanization accelerator in the rubber industry, an antioxidant in polymers, and a fungicide in agriculture. It is also a known intermediate in the synthesis of other sulfur-containing compounds. '

4,4'-dithiodimorpholine: rubber vulcanizing agent causing occupational dermatitis; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID7648
CHEMBL ID582932
SCHEMBL ID137538
MeSH IDM0062169

Synonyms (96)

Synonym
brn 0126214
dimorpholine n,n'-disulfide
vanax a
ccris 8923
morpholine, n,n'-disulfide-
n,n'-dithiodimorfolin [czech]
einecs 203-103-0
sanfel r
ai3-08625
morpholinodisulfide
hsdb 5351
deovulc m
vulnoc
4,4'-dithiobismorpholine
di(morpholin-4-yl) disulphide
morpholine, 4,4'-dithiodi-
nsc 65239
dimorpholino disulfide
morpholine,4'-dithiodi-
bismorpholino disulfide
n,n-dithiodimorpholine
morpholine,4'-dithiobis-
sulfasan r
morpholine disulfide
sulfasan
4,4'-dithiomorpholine
n,n'-bismorpholine disulfide
wln: t6n dotj ass-at6n dotj
disulfide, dimorpholino-
morpholino disulfide
n,n'-dithiodimorpholine
usaf ek-t-6645
usaf b-17
dithiobis(morpholine)
nsc-65239
accel r
4,4'-dithiobis(morpholine)
dithiobismorpholine
dimorpholine disulfide
morpholine, 4,4'-dithiobis-
103-34-4
4-(morpholinodisulfanyl)morpholine
4,4'-dithiodimorpholine
nsc65239
NCIOPEN2_003134
n,n'-dimorpholine disulfide
n,n'-dithiobis(morpholine)
D0282
inchi=1/c8h16n2o2s2/c1-5-11-6-2-9(1)13-14-10-3-7-12-8-4-10/h1-8h2
hlbzwyxlqjqbku-uhfffaoysa-
4-morpholin-4-yldisulfanylmorpholine
4-(morpholin-4-yldisulfanyl)morpholine
dithiodimorpholine
CHEMBL582932
FT-0657982
NCGC00249116-01
tox21_303110
cas-103-34-4
dtxsid8026698 ,
dtxcid706698
NCGC00257082-01
tox21_201775
NCGC00259324-01
4,4-dithiodimorpholine
bdbm50414924
unii-m786p489yf
n,n'-dithiodimorfolin
ec 203-103-0
m786p489yf ,
4-27-00-00613 (beilstein handbook reference)
AKOS015897388
4,4'-disulfanediyldimorpholine
STL326287
SCHEMBL137538
dithiodimorpholine, 4,4'-
4,4'-dithiodimorpholine [hsdb]
4,4'-dithiodimorpholine [mi]
morpholine n,n'-disulfide
4,4'-dimorpholine disulphide
morpholine, n,n'-disulfide
4-(4-morpholinyldisulfanyl)morpholine #
akrochem accelerator r
naugex sd-1
sulfazan r
dimorpholinodisulfide
bis(4-morpholinyl)disulfide
mfcd00023319
AS-57709
4-(4-morpholinyldisulfanyl)morpholine
1,2-dimorpholinodisulfane
4,4'-dithio-dimorpholine
CS-0196466
4,4/'-dithiodimorpholine
E78171
Q27283591
n,n'-dimorpholinedisulfide
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (33)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
acetylcholinesteraseHomo sapiens (human)Potency70.28560.002541.796015,848.9004AID1347395
hypoxia-inducible factor 1 alpha subunitHomo sapiens (human)Potency61.03443.189029.884159.4836AID1224846
RAR-related orphan receptor gammaMus musculus (house mouse)Potency23.06170.006038.004119,952.5996AID1159521; AID1159523
SMAD family member 2Homo sapiens (human)Potency51.45650.173734.304761.8120AID1346859; AID1346924
SMAD family member 3Homo sapiens (human)Potency51.45650.173734.304761.8120AID1346859; AID1346924
GLI family zinc finger 3Homo sapiens (human)Potency32.48410.000714.592883.7951AID1259368; AID1259369; AID1259392
AR proteinHomo sapiens (human)Potency62.35690.000221.22318,912.5098AID1259243; AID1259247; AID743035; AID743042; AID743063
caspase 7, apoptosis-related cysteine proteaseHomo sapiens (human)Potency76.17690.013326.981070.7614AID1346978
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency72.03480.000657.913322,387.1992AID1259377; AID1259378
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency67.29170.001022.650876.6163AID1224838; AID1224893
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency46.08760.000214.376460.0339AID720692
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency64.67950.003041.611522,387.1992AID1159552; AID1159553; AID1159555
retinoid X nuclear receptor alphaHomo sapiens (human)Potency20.61440.000817.505159.3239AID1159527; AID1159531
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency53.98600.001530.607315,848.9004AID1224841; AID1224842; AID1224848; AID1224849; AID1259401; AID1259403
farnesoid X nuclear receptorHomo sapiens (human)Potency61.03440.375827.485161.6524AID743217
pregnane X nuclear receptorHomo sapiens (human)Potency64.51170.005428.02631,258.9301AID1346982
estrogen nuclear receptor alphaHomo sapiens (human)Potency54.51820.000229.305416,493.5996AID1259244; AID743069; AID743075
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency48.96620.001019.414170.9645AID743191
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency46.63080.023723.228263.5986AID743222; AID743223; AID743241
caspase-3Homo sapiens (human)Potency76.17690.013326.981070.7614AID1346978
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency68.24110.001723.839378.1014AID743083
activating transcription factor 6Homo sapiens (human)Potency43.64120.143427.612159.8106AID1159516
v-jun sarcoma virus 17 oncogene homolog (avian)Homo sapiens (human)Potency54.97090.057821.109761.2679AID1159526; AID1159528
Histone H2A.xCricetulus griseus (Chinese hamster)Potency45.09770.039147.5451146.8240AID1224845; AID1224896
Caspase-7Cricetulus griseus (Chinese hamster)Potency27.16730.006723.496068.5896AID1346980
caspase-3Cricetulus griseus (Chinese hamster)Potency27.16730.006723.496068.5896AID1346980
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency62.03920.000323.4451159.6830AID743065; AID743067
heat shock protein beta-1Homo sapiens (human)Potency56.01490.042027.378961.6448AID743210; AID743228
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency34.02700.000627.21521,122.0200AID743202
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency68.58960.001557.789015,848.9004AID1259244
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency68.58960.001551.739315,848.9004AID1259244
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Fatty-acid amide hydrolase 1Homo sapiens (human)IC50 (µMol)1,000.00000.00020.59827.0000AID441698
Monoglyceride lipaseHomo sapiens (human)IC50 (µMol)11.22020.00091.126810.0000AID441697
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (13)

Processvia Protein(s)Taxonomy
fatty acid catabolic processFatty-acid amide hydrolase 1Homo sapiens (human)
arachidonic acid metabolic processFatty-acid amide hydrolase 1Homo sapiens (human)
positive regulation of vasoconstrictionFatty-acid amide hydrolase 1Homo sapiens (human)
monoacylglycerol catabolic processFatty-acid amide hydrolase 1Homo sapiens (human)
lipid metabolic processMonoglyceride lipaseHomo sapiens (human)
fatty acid biosynthetic processMonoglyceride lipaseHomo sapiens (human)
inflammatory responseMonoglyceride lipaseHomo sapiens (human)
regulation of signal transductionMonoglyceride lipaseHomo sapiens (human)
arachidonic acid metabolic processMonoglyceride lipaseHomo sapiens (human)
triglyceride catabolic processMonoglyceride lipaseHomo sapiens (human)
acylglycerol catabolic processMonoglyceride lipaseHomo sapiens (human)
regulation of inflammatory responseMonoglyceride lipaseHomo sapiens (human)
regulation of sensory perception of painMonoglyceride lipaseHomo sapiens (human)
monoacylglycerol catabolic processMonoglyceride lipaseHomo sapiens (human)
regulation of endocannabinoid signaling pathwayMonoglyceride lipaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (8)

Processvia Protein(s)Taxonomy
protein bindingFatty-acid amide hydrolase 1Homo sapiens (human)
phospholipid bindingFatty-acid amide hydrolase 1Homo sapiens (human)
fatty acid amide hydrolase activityFatty-acid amide hydrolase 1Homo sapiens (human)
identical protein bindingFatty-acid amide hydrolase 1Homo sapiens (human)
acylglycerol lipase activityFatty-acid amide hydrolase 1Homo sapiens (human)
amidase activityFatty-acid amide hydrolase 1Homo sapiens (human)
lysophospholipase activityMonoglyceride lipaseHomo sapiens (human)
protein bindingMonoglyceride lipaseHomo sapiens (human)
protein homodimerization activityMonoglyceride lipaseHomo sapiens (human)
acylglycerol lipase activityMonoglyceride lipaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (6)

Processvia Protein(s)Taxonomy
endoplasmic reticulum membraneFatty-acid amide hydrolase 1Homo sapiens (human)
cytoskeletonFatty-acid amide hydrolase 1Homo sapiens (human)
organelle membraneFatty-acid amide hydrolase 1Homo sapiens (human)
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
endoplasmic reticulum membraneMonoglyceride lipaseHomo sapiens (human)
cytosolMonoglyceride lipaseHomo sapiens (human)
plasma membraneMonoglyceride lipaseHomo sapiens (human)
membraneMonoglyceride lipaseHomo sapiens (human)
membraneMonoglyceride lipaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (8)

Assay IDTitleYearJournalArticle
AID441697Inhibition of human MGL activity using [3H]2-oleoylglycerol substrate by liquid scintillation counting2009Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22
Bis(dialkylaminethiocarbonyl)disulfides as potent and selective monoglyceride lipase inhibitors.
AID477881Antiproliferative activity against BCA2 and ER deficient human MDA-MB-231 cells after 72 hrs by MTT assay2010Journal of medicinal chemistry, Apr-08, Volume: 53, Issue:7
Exploring the structural requirements for inhibition of the ubiquitin E3 ligase breast cancer associated protein 2 (BCA2) as a treatment for breast cancer.
AID477883Antiproliferative activity against human T47D cells expressing BCA2 and estrogen receptor after 72 hrs by MTT assay2010Journal of medicinal chemistry, Apr-08, Volume: 53, Issue:7
Exploring the structural requirements for inhibition of the ubiquitin E3 ligase breast cancer associated protein 2 (BCA2) as a treatment for breast cancer.
AID477884Antiproliferative activity against human MCF10A cells after 72 hrs by MTT assay2010Journal of medicinal chemistry, Apr-08, Volume: 53, Issue:7
Exploring the structural requirements for inhibition of the ubiquitin E3 ligase breast cancer associated protein 2 (BCA2) as a treatment for breast cancer.
AID441696Inhibition of human MGL activity using [3H]2-oleoylglycerol substrate at 10 uM by liquid scintillation counting2009Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22
Bis(dialkylaminethiocarbonyl)disulfides as potent and selective monoglyceride lipase inhibitors.
AID441698Inhibition of human recombinant FAAH-maltose binding protein2009Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22
Bis(dialkylaminethiocarbonyl)disulfides as potent and selective monoglyceride lipase inhibitors.
AID477880Antiproliferative activity against human MCF7 cells expressing BCA2 and estrogen receptor after 72 hrs by MTT assay2010Journal of medicinal chemistry, Apr-08, Volume: 53, Issue:7
Exploring the structural requirements for inhibition of the ubiquitin E3 ligase breast cancer associated protein 2 (BCA2) as a treatment for breast cancer.
AID477882Antiproliferative activity against human MDA-MB-231 cells expressing BCA2 and ERalpha after 72 hrs by MTT assay2010Journal of medicinal chemistry, Apr-08, Volume: 53, Issue:7
Exploring the structural requirements for inhibition of the ubiquitin E3 ligase breast cancer associated protein 2 (BCA2) as a treatment for breast cancer.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (9)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905 (55.56)18.7374
1990's1 (11.11)18.2507
2000's1 (11.11)29.6817
2010's2 (22.22)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 22.60

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index22.60 (24.57)
Research Supply Index2.40 (2.92)
Research Growth Index4.41 (4.65)
Search Engine Demand Index21.17 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (22.60)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies1 (10.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (90.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
disulfiram
[no description available]		2.4620organic disulfide;
organosulfur acaricide		angiogenesis inhibitor;
antineoplastic agent;
apoptosis inducer;
EC 1.2.1.3 [aldehyde dehydrogenase (NAD(+))] inhibitor;
EC 3.1.1.1 (carboxylesterase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
ferroptosis inducer;
fungicide;
NF-kappaB inhibitor
thiram
Thiram: A dithiocarbamate chemical, used commercially in the rubber processing industry and as a fungicide. In vivo studies indicate that it inactivates the enzyme GLUTATHIONE REDUCTASE. It has mutagenic activity and may induce chromosomal aberrations.. thiram : An organic disulfide that results from the formal oxidative dimerisation of N,N-dimethyldithiocarbamic acid. It is widely used as a fungicidal seed treatment.		2.0510organic disulfideantibacterial drug;
antifungal agrochemical;
antiseptic drug
isoprene
isoprene: used in manufacture of ''synthetic'' rubber, butyl rubber; copolymer in production of elastomers; structure. isoprene : A hemiterpene with the formula CH2=C(CH3)CH=CH2; the monomer of natural rubber and a common structure motif to the isoprenoids, a large class of other naturally occurring compounds.		2.3720alkadiene;
hemiterpene;
volatile organic compound		plant metabolite
bis(1-piperidylthiocarbonyl)disulfide
bis(1-piperidylthiocarbonyl)disulfide: indicator for analysis of copper; structure		2.4620
benzothiazole
benzothiazole: structure. benzothiazole : An organic heterobicyclic compound that is a fusion product between benzene and thiazole. The parent of the class of benzothiazoles.		1.9610benzothiazolesenvironmental contaminant;
plant metabolite;
xenobiotic
tetramethylthiuram monosulfide
[no description available]		2.0510
n-oxydiethylene-2-benzothiazole sulfenamide
N-oxydiethylene-2-benzothiazole sulfenamide: structure in first source		2.3720
morpholine
[no description available]		2.3720morpholines;
saturated organic heteromonocyclic parent		NMR chemical shift reference compound
thiazoles
[no description available]		2.66301,3-thiazoles;
mancude organic heteromonocyclic parent;
monocyclic heteroarene
methyl diethyldithiocarbamate
[no description available]		2.0510
benzenesulfohydrazide
benzenesulfohydrazide: structure in first source		1.9610
lopinavir
[no description available]		2.0610amphetamines;
dicarboxylic acid diamide		anticoronaviral agent;
antiviral drug;
HIV protease inhibitor
captax
captax: RN given refers to parent cpd. 1,3-benzothiazole-2-thiol : 1,3-Benzothiazole substituted at the 2-position with a sulfanyl group.		2.3720aryl thiol;
benzothiazoles		carcinogenic agent;
metabolite
arachidonyltrifluoromethane
arachidonyltrifluoromethane: structure given in first source; inhibits 85-kDa phospholipase A2. AACOCF3 : A fatty acid derivative that is arachidonic acid in which the OH part of the carboxy group has been replaced by a trifluoromethyl group		2.0510fatty acid derivative;
ketone;
olefinic compound;
organofluorine compound		EC 3.1.1.4 (phospholipase A2) inhibitor
diamide
Diamide: A sulfhydryl reagent which oxidizes sulfhydryl groups to the disulfide form. It is a radiation-sensitizing agent of anoxic bacterial and mammalian cells.		2.06101,1'-azobis(N,N-dimethylformamide)
azodicarbonamide
[no description available]		2.0610organic molecular entity
cay 10499
[no description available]		2.0510carbamate ester
methyl arachidonylfluorophosphonate
[no description available]		2.0510phosphonic ester
urb602
URB602: inhibitor of 2-arachidonoylglycerol (2-AG)-deactivating enzyme, monoacylglycerol lipase, structure in first source		2.0510
ly2183240
LY2183240: structure in first source		2.0510biphenyls
pyrimidinones
Pyrimidinones: Heterocyclic compounds known as 2-pyrimidones (or 2-hydroxypyrimidines) and 4-pyrimidones (or 4-hydroxypyrimidines) with the general formula C4H4N2O.		2.0610
ConditionIndicatedRelationship StrengthStudiesTrials
Breast Cancer
[description not available]		02.0510
Breast Neoplasms
Tumors or cancer of the human BREAST.		02.0510
HPV Infection
[description not available]		02.4320
Papillomavirus Infections
Neoplasms of the skin and mucous membranes caused by papillomaviruses. They are usually benign but some have a high risk for malignant progression.		02.4320
Eye Abnormalities
Congenital absence of or defects in structures of the eye; may also be hereditary.		01.9610
Poultry Diseases
Diseases of birds which are raised as a source of meat or eggs for human consumption and are usually found in barnyards, hatcheries, etc. The concept is differentiated from BIRD DISEASES which is for diseases of birds not considered poultry and usually found in zoos, parks, and the wild.		01.9610
Abnormalities, Drug-Induced
Congenital abnormalities caused by medicinal substances or drugs of abuse given to or taken by the mother, or to which she is inadvertently exposed during the manufacture of such substances. The concept excludes abnormalities resulting from exposure to non-medicinal chemicals in the environment.		01.9610
Cancer of Cervix
[description not available]		0210
Fibroma, Shope
[description not available]		0210
Uterine Cervical Neoplasms
Tumors or cancer of the UTERINE CERVIX.		0210
Abnormalities, Autosome
[description not available]		01.9710